|
|
Vaccine Detail
|
HLA-A1-Binding MAGE-1/MAGE-3 Multipeptide-Pulsed Autologous Dendritic Cell Vaccine |
| Vaccine Information |
- Vaccine Name: HLA-A1-Binding MAGE-1/MAGE-3 Multipeptide-Pulsed Autologous Dendritic Cell Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007495
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: MAGEA3, MAGEA1
- MAGEA3
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- MAGEA1 (MAGE1)
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Description: A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with human leukocyte antigen (HLA)-A1-binding melanoma-associated antigen peptides MAGE-1 and MAGE-3 with potential immunomodulating and antineoplastic activity. Upon vaccination, HLA-A1-binding MAGE-1/MAGE-3 multipeptide-pulsed autologous dendritic cell vaccine may stimulate the host immune system to mount an anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against MAGE1- and MAGE-3-expressing cancer cells, resulting in tumor cell lysis. HLA-A1 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A1 may improve antigenic peptide immunogenicity. (NCIT_C90570).
|
| Host Response |
|
|
| References |
NCIT_C90570: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C90570]
|
|
